Lore Wils

Lore Wils

Auto-generated profile, based on publicly available information

Lore Wils

Laboratory for Advanced Disease Modelling, Targeted Drug Discovery and Gene Therapy (ADVANTAGE), Herestraat 49, Leuven, Belgium

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
EPEline Pellaers
Eline Pellaers
JJJulie Janssens
Julie Janssens
LWLore Wils
Lore Wils
ADAlexe Denis
Alexe Denis
ABAnayat Bhat
Anayat Bhat
ZDZeger Debyser
Zeger Debyser
The persistence of HIV-1 in a latent state within long-lived immune cells remains a major barrier to a cure for HIV-1 infection. The “block-and-lock” strategy aims to silence the HIV-1 provirus permanently using latency promoting agents (LPAs). LEDGINs, a well-known class of LPAs, inhibit the interaction between viral integrase and LEDGF/p75, reducing viral integration and retargeting the provirus to regions resistant to reactivation. However, proximity to enhancers may still permit residual transcription. Given BRD4’s central role in the enhancer biology, we now test two BRD4 modulators, JQ1 and ZL0580. Mechanistic studies reveal that JQ1 and ZL0580 have contrasting effects on Tat-dependent HIV-1 transcription, resulting in JQ1 promoting viral reactivation and ZL0580 inducing transcriptional silencing. Combining ZL0580 with LEDGINs has an additive effect in blocking HIV-1 transcription and reactivation, in both cell lines and primary cells. These findings demonstrate the potential of ZL0580 to enhance the block-and-lock cure strategy.